A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
This is a Phase III, two-arm, randomized, double-blind, global, multicenter study assessing the efficacy and safety of rilvegostomig compared to pembrolizumab, both in combination with platinum-based doublet chemotherapy, as a first-line (1L) treatment for patients with squamous locally advanced or metastatic non-small cell lung cancer (mNSCLC) whose tumors express PD-L1 (tumor cells (TC) ≥ 1%).
Inclusion Criteria:
Exclusion Criteria:
information.center@astrazeneca.com1-877-240-9479
CABA, 1425, Argentina
Gyöngyös - Mátraháza, 3200, Hungary
Amagasaki-shi, 660-8550, Japan
Hirakata-shi, 573-1191, Japan
Kawagoe-shi, 350-8550, Japan
Kawasaki-shi, 216-8511, Japan
Kitaadachi-gun, 362-0806, Japan
Kitakyushu-shi, 807-8555, Japan
Matsusaka-shi, 515-8544, Japan
Ota-shi, 373-8550, Japan
Saitama-shi, 338-0001, Japan
Shinjuku-ku, 160-0023, Japan
Takaoka-shi, 933-8555, Japan
Changwon-si, 51353, South Korea
JinJoo, 52727, South Korea
Greater London, SW3 6JJ, United Kingdom